India
· Delayed Price · Currency is INR | Market Cap | 33.61B |
| Revenue (ttm) | 26.50B |
| Net Income (ttm) | -1.10B |
| Shares Out | 156.78M |
| EPS (ttm) | -7.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,348 |
| Average Volume | 298,477 |
| Open | 215.60 |
| Previous Close | 215.61 |
| Day's Range | 213.50 - 218.55 |
| 52-Week Range | 133.00 - 307.98 |
| Beta | 0.90 |
| RSI | 57.85 |
| Earnings Date | May 26, 2025 |
About Dishman Carbogen Amcis
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutica... [Read more]
Financial Performance
In 2023, Dishman Carbogen Amcis's revenue was 26.16 billion, an increase of 8.41% compared to the previous year's 24.13 billion. Losses were -1.53 billion, 414.9% more than in 2022.
Financial StatementsNews
Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China
Dishman Carbogen Amcis Ltd. witnessed a 5% jump in its share price after announcing a significant regulatory milestone. Its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has secured a D...
Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China
Dishman Carbogen Amcis Ltd. has announced that its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Products Administrat...
Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance
Shares of Dishman Carbogen Amcis Ltd gained 1.90% to ₹210.22 on Wednesday after the company’s board approved the issuance of rated, listed, senior, secured, redeemable, taxable non-convertible debentu...
Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility
CARBOGEN AMCIS AG, a subsidiary of Dishman Carbogen Amcis Limited, has announced the successful completion of a Swissmedic inspection at its Vionnaz facility in Switzerland. This achievement reaffirms...